TY - JOUR
T1 - Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease
T2 - Insights from the PROMISE trial
AU - PROMISE Investigators
AU - Pagidipati, Neha J.
AU - Coles, Adrian
AU - Hemal, Kshipra
AU - Lee, Kerry L.
AU - Dolor, Rowena J.
AU - Pellikka, Patricia A.
AU - Mark, Daniel B.
AU - Patel, Manesh R.
AU - Litwin, Sheldon E.
AU - Daubert, Melissa A.
AU - Shah, Svati H.
AU - Hoffmann, Udo
AU - Douglas, Pamela S.
N1 - Funding Information:
D. B. M. reported receiving personal fees from Medtronic, CardioDx, and St Jude Medical and grant support from Eli Lilly, Bristol-Myers Squibb, Gilead Sciences, AGA Medical, Merck, Oxygen Biotherapeutics, and AstraZeneca. M. R. P. reported receiving grant support from Astra Zeneca, CSL, Heart Flow Technologies, Jansen, Johnson & Johnson, MAQUET, Medtronic, and the NHLBI and serving on advisory boards for Astra Zeneca, Bayer, CSL, Genzyme Corp., Janssen, Medtronic, and Merck. U. H. reported receiving grant support from Siemens Healthcare and HeartFlow. P. S. D. reported receiving grant support from HeartFlow and serves on a data and safety monitoring board for GE Healthcare. No other author reported relevant disclosures.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/2
Y1 - 2019/2
N2 - Background: Although sex differences exist in the management of acute coronary syndromes, less is known about the management and outcomes of women and men with suspected coronary artery disease being evaluated with noninvasive testing (NIT). Methods: We investigated sex-based differences in NIT results and subsequent clinical management in 4,720 women and 4,246 men randomized to CT angiography versus stress testing in the PROMISE trial. Logistic regression models assessed relationships between sex and referral for catheterization, revascularization, and aspirin or statin use. Cox regression models assessed the relationship between sex and the composite of all-cause death, myocardial infarction, or unstable angina. Results: Women more often had normal NITs than men (61.0% vs 49.6%, P <.001) and less often had mild (29.3% vs 35.4%, P <.001), moderate (4.0% vs 6.8%, P <.001), or severe abnormalities (5.7% vs 8.3%, P <.001) found on NIT. Women were less likely to be referred for catheterization than men (7.6% vs 12.6%, adjusted OR 0.75 [0.62-0.90]; P =.002). Of those who underwent catheterization within 90 days of randomization (358 women, 534 men), fewer women than men had obstructive coronary artery disease (40.8% vs 60.9%, P <.001). At a 60-day visit, women were significantly less likely than men to report statin use when indicated (adjusted OR 0.81 [0.73-0.91]; P <.001) but were similarly likely to report aspirin use when indicated (adjusted OR 0.78 [0.56-1.08]; P =.13). Over a median follow-up of 25 months, women had better outcomes than men (adjusted OR 0.73 [0.57-0.94]; P =.017). Conclusions: Although women more frequently had normal NITs compared with men, those with abnormalities on NIT were less likely to be referred for catheterization or to receive statin therapy. The high rates of negative NIT in women, coupled with the better outcomes compared with men, strongly support the need for a sex-specific algorithm to guide NIT and chest pain management.
AB - Background: Although sex differences exist in the management of acute coronary syndromes, less is known about the management and outcomes of women and men with suspected coronary artery disease being evaluated with noninvasive testing (NIT). Methods: We investigated sex-based differences in NIT results and subsequent clinical management in 4,720 women and 4,246 men randomized to CT angiography versus stress testing in the PROMISE trial. Logistic regression models assessed relationships between sex and referral for catheterization, revascularization, and aspirin or statin use. Cox regression models assessed the relationship between sex and the composite of all-cause death, myocardial infarction, or unstable angina. Results: Women more often had normal NITs than men (61.0% vs 49.6%, P <.001) and less often had mild (29.3% vs 35.4%, P <.001), moderate (4.0% vs 6.8%, P <.001), or severe abnormalities (5.7% vs 8.3%, P <.001) found on NIT. Women were less likely to be referred for catheterization than men (7.6% vs 12.6%, adjusted OR 0.75 [0.62-0.90]; P =.002). Of those who underwent catheterization within 90 days of randomization (358 women, 534 men), fewer women than men had obstructive coronary artery disease (40.8% vs 60.9%, P <.001). At a 60-day visit, women were significantly less likely than men to report statin use when indicated (adjusted OR 0.81 [0.73-0.91]; P <.001) but were similarly likely to report aspirin use when indicated (adjusted OR 0.78 [0.56-1.08]; P =.13). Over a median follow-up of 25 months, women had better outcomes than men (adjusted OR 0.73 [0.57-0.94]; P =.017). Conclusions: Although women more frequently had normal NITs compared with men, those with abnormalities on NIT were less likely to be referred for catheterization or to receive statin therapy. The high rates of negative NIT in women, coupled with the better outcomes compared with men, strongly support the need for a sex-specific algorithm to guide NIT and chest pain management.
UR - http://www.scopus.com/inward/record.url?scp=85057806349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057806349&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2018.11.002
DO - 10.1016/j.ahj.2018.11.002
M3 - Article
C2 - 30529930
AN - SCOPUS:85057806349
SN - 0002-8703
VL - 208
SP - 28
EP - 36
JO - American heart journal
JF - American heart journal
ER -